Press releaseGlobe Newswire
Climb Bio
CLYM · NASDAQ
$10.80+$1.07 (+11.00%)TodayMarket closed ·
Prev close $9.73
Latest news
- NewsVandana Singh
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule
- Press releaseGlobe Newswire
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
- Press releaseGlobe Newswire
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
- NewsVandana Singh
Why Is Climb Bio Stock Gaining Friday?
- Press releaseGlobe Newswire
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
- Press releaseGlobe Newswire
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
- Press releaseGlobe Newswire
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
- Press releaseGlobe Newswire
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
- Press releaseGlobe Newswire
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
- Press releaseGlobe Newswire
Climb Bio, Inc. Announces $110.0 Million Private Placement
- Press releaseGlobe Newswire
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsVandana Singh
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
- Press releaseGlobe Newswire
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
- Press releaseGlobe Newswire
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
- Press releaseGlobe Newswire
Climb Bio to Present at Upcoming September 2025 Investor Conferences
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
- Press releasePRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Climb Bio, Inc. (NASDAQ: CLYM)
- Press releaseGlobe Newswire
Climb Bio to Present at Upcoming Investor Conferences
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.